Core Insights - AskGene Pharma, a subsidiary of Aosaikang, has entered into a licensing agreement with Visara for its innovative drug project ASK712, which is currently in Phase IIa clinical trials for treating macular diseases [1] Licensing Agreement Details - The licensing agreement grants Visara exclusive rights to develop, manufacture, and commercialize ASK712 in several regions, including Greater China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, South Korea, and India [1] - Visara will pay an upfront fee of $7 million to AskGene Pharma, with potential milestone payments related to research, registration, and commercialization that could total up to $89 million [1] - AskGene Pharma will also receive a percentage of royalties based on the annual net sales of the product within the licensed regions [1]

Core Viewpoint - Heng Rui Medicine has entered into an agreement with Braveheart Bio to license its innovative drug HRS-1893 for a total of $75 million, with potential milestone payments reaching up to $1.013 billion based on clinical development and sales performance [1][2]. Group 1: Agreement Details - Heng Rui Medicine will grant Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]. - Braveheart Bio will pay an upfront fee of $65 million, consisting of $32.5 million in cash and $32.5 million in equity, along with a $10 million milestone payment upon completion of technology transfer, totaling $75 million [1]. - Heng Rui Medicine is eligible for additional milestone payments related to clinical development and sales, which could reach up to $1.013 billion [1]. Group 2: Drug Information - HRS-1893 is a myosin selective inhibitor that works by inhibiting the ATPase activity of cardiac myosin, thereby reducing excessive contraction of the myocardium, decreasing left ventricular hypertrophy, and improving diastolic relaxation [2]. - The drug is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [2].

Group 1 - Company Heng Rui Medicine (600276.SH) has entered into an agreement with Braveheart Bio, Inc. to license its innovative drug HRS-1893, which has independent intellectual property rights [1] - The licensing agreement grants Braveheart Bio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - Braveheart Bio will pay a total of $75 million to Heng Rui, which includes a $65 million upfront payment and a $10 million milestone payment upon completion of technology transfer [1] Group 2 - HRS-1893 is a myosin selective inhibitor that works by inhibiting the activity of cardiac myosin ATPase, thereby reducing excessive myocardial contraction, decreasing left ventricular hypertrophy, and improving diastolic relaxation [2] - The drug is currently in Phase III clinical development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) [2]